Showing results (401-410 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|December 3, 2021
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care recordsJonathan Pearson-Stuttard, Yiling J Cheng, James Bennett, et al.
The Lancet. Diabetes & Endocrinology|November 18, 2021
Glycaemic management in diabetes: old and new approachesAntonio Ceriello, Francesco Prattichizzo, Moshe Phillip, et al.
The Lancet. Diabetes & Endocrinology|September 2, 2018
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological studyClara K Chow, Chinthanie Ramasundarahettige, Weihong Hu, et al.
The Lancet. Diabetes & Endocrinology|October 6, 2018
Public health and health systems: implications for the prevention and management of type 2 diabetes in south AsiaAndrew P Hills, Anoop Misra, Jason M R Gill, et al.
The Lancet. Diabetes & Endocrinology|June 9, 2019
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trialAlexander Dimitri Miras, Belén Pérez-Pevida, Madhawi Aldhwayan, et al.
The Lancet. Diabetes & Endocrinology|October 31, 2021
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
The Lancet. Diabetes & Endocrinology|March 6, 2022
Obesity in children and adolescents: epidemiology, causes, assessment, and managementHiba Jebeile, Aaron S Kelly, Grace O'Malley, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2022
Risks and burdens of incident diabetes in long COVID: a cohort studyYan Xie, Ziyad Al-Aly
The Lancet. Diabetes & Endocrinology|June 14, 2019
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trialVanita R Aroda, Guillermo González-Galvez, Randi Grøn, et al.
The Lancet. Diabetes & Endocrinology|May 4, 2019
Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial dataJohn M Dennis, Beverley M Shields, William E Henley, et al.
Pageof 93